A Quality Improvement Project Implementing PrEP Academic Detailing to Impact Provider Knowledge, Attitudes, and Behavior in a Primary Care Setting

Background: In 2012 the U.S. Food and Drug Administration (FDA) approved the drug emtricitabine/tenofovir for use as Human Immunodeficiency Virus (HIV) pre-exposure prophylaxis (PrEP) after proving to be safe and effective at preventing HIV in multiple peer-reviewed studies. Despite the proven safety and value of PrEP treatment, use remains low in practice.